Page 70 - TD-4-2

Tumor Discovery Glioblastoma treating fields system

parameters, offering the flexibility to optimize treatment whether TTF influences neuroinflammation, neuronal
for individual patients or different tumor types. plasticity, or cognitive function could inform strategies to
The observed inhibition of glioblastoma cell enhance safety and mitigate any potential neurotoxicity.
proliferation and tumor progression in our models 4.4. Future directions and clinical translation
aligns with previous research indicating that alternating
electric fields disrupt mitotic spindle formation, interfere Despite promising preclinical results, translation of
with tubulin polymerization, and induce apoptosis in our newly developed TTF system into clinical practice
rapidly dividing cancer cells. Importantly, the in vitro requires further experimental validation. Future studies
findings demonstrated a dose-dependent response, with should include large-scale animal models with longer
higher electric field intensities leading to greater tumor treatment durations to assess long-term efficacy and safety.
suppression. This suggests the potential for further In addition, clinical trials will be necessary to determine
optimizing field strength and exposure duration to whether the advantages observed in our preclinical models
maximize efficacy while maintaining safety. translate into meaningful benefits for GBM patients.
One promising direction is the integration of real-time
4.2. Comparison with existing TTF devices monitoring and feedback control in TTF therapy. Advanced
At present, the FDA-approved Optune system represents sensor technologies and machine learning algorithms could
the benchmark for TTF therapy. However, it is limited by be employed to personalize treatment based on tumor
its relatively static field distribution and reliance on external response dynamics. This precision medicine approach could
wearable electrodes. Our system’s integration of high- optimize electric field parameters in real time, maximizing
dielectric ceramic electrodes addresses these limitations therapeutic effects while minimizing unnecessary exposure.
by ensuring more efficient electric field penetration and a Another avenue for exploration is the combination of
more homogenous distribution over tumor-affected areas. TTF therapy with other modalities such as hyperthermia,
In addition, our system’s control module enables dynamic photodynamic therapy, and nanomedicine-based drug
field modulation, which could provide greater adaptability delivery. These synergies may enhance tumor sensitivity to
in treating heterogeneous and irregularly shaped tumors. TTF while overcoming some of the resistance mechanisms
Moreover, while the Optune system has demonstrated associated with conventional treatments. In addition,
survival benefits when combined with temozolomide investigating TTF’s applicability to other aggressive
chemotherapy, its efficacy remains suboptimal for some cancers, such as pancreatic or lung cancers, could broaden
patient populations. Our system presents an opportunity its clinical impact.
to explore combination therapies, such as pairing TTF with
immunotherapies, targeted inhibitors, or gene therapies. 5. Conclusion
This combinatorial approach could further enhance Our study presents a comprehensive and systematic
treatment outcomes and extend survival benefits beyond approach to the development and evaluation of an
what is currently achievable with standard TTF therapy. advanced TTF therapy system for GBM. By incorporating
high-dielectric ceramic electrodes and a modular control
4.3. Safety and tolerability considerations
system, we demonstrated improvements in electric field
One of the primary concerns associated with TTF therapy transmission and therapeutic efficacy compared to existing
is the potential for adverse effects such as skin irritation TTF devices. The preclinical results showed that our system
and discomfort at electrode attachment sites. Our study effectively inhibited glioblastoma cell proliferation in vitro
monitored physiological responses in rat models and and reduced tumor growth in vivo, supporting its potential
observed only mild skin irritation, which did not progress as a novel approach for GBM treatment.
to severe tissue damage. This suggests that our electrode Importantly, our study also highlighted the need for
design minimizes localized heating and mechanical stress. further validation of the therapy system to establish its
Future research should focus on developing bioadaptive clinical significance. While our device demonstrated
materials that further reduce skin irritation and improve promising results in preclinical models, additional studies
patient compliance.
are required to assess its comparative efficacy, safety
In addition, concerns regarding TTF’s effects on normal profile, and ease of integration into standard treatment
brain tissue and neural function remain largely unexplored. regimens. The findings suggest that while improved
While TTF selectively targets rapidly dividing cells, electrode materials and field modulation strategies may
understanding its long-term impact on the surrounding offer advantages, these benefits must be rigorously tested
neural microenvironment is essential. Investigating in larger, more diverse experimental models.

Volume 4 Issue 2 (2025) 62 doi: 10.36922/td.7171